SPANXA2 and coronary artery disorder: Specifically, we propose that SPANXA2-OT1 modulates the chemokine profile of macrophages by acting as a competing endogenous RNA for miR-338, thereby relieving its suppressive effect on IL-8 and promoting IL-8 expression, which, in turn, may enhance macrophage chemotaxis and inflammatory activation in CAD.